{"id":"placebo-matching-lapatinib","safety":{"commonSideEffects":[{"rate":"60","effect":"Diarrhea"},{"rate":"15","effect":"Hand-foot skin reaction"},{"rate":"40","effect":"Nausea"},{"rate":"25","effect":"Fatigue"},{"rate":"15","effect":"Rash"},{"rate":"5","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lapatinib irreversibly inhibits the intracellular tyrosine kinases of human epidermal growth factor receptors HER2 and EGFR. By blocking these growth-promoting pathways, it prevents phosphorylation and downstream signaling that drives proliferation in HER2-positive and EGFR-dependent cancers. This dual inhibition makes it effective in breast cancer and other solid tumors dependent on these receptors.","oneSentence":"Lapatinib is a small-molecule tyrosine kinase inhibitor that blocks HER2 and EGFR signaling to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:09.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive advanced or metastatic breast cancer (in combination with capecitabine or letrozole)"},{"name":"HER2-positive breast cancer (adjuvant treatment)"}]},"trialDetails":[{"nctId":"NCT00281658","phase":"PHASE3","title":"Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-01-02","conditions":"Neoplasms, Breast","enrollment":444},{"nctId":"NCT00073528","phase":"PHASE3","title":"Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-12-09","conditions":"Breast Neoplasms","enrollment":1286},{"nctId":"NCT01328054","phase":"PHASE4","title":"A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12","conditions":"Cancer","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo matching lapatinib","genericName":"placebo matching lapatinib","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lapatinib is a small molecule used to treat cancer, specifically breast neoplasms, as a medication. In clinical trials, lapatinib has been compared to a placebo matching lapatinib to evaluate its effects on the QTc interval.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}